A user diagnosed with Crohn's disease is concerned it might contribute to balding. They have been using keto shampoo, finasteride, and oral minoxidil, which improved their hair but not significantly.
The conversation discusses experiences with hair loss treatments containing RootBioTec and Anagain. Users share their results and compare these treatments to Minoxidil, finasteride, and RU58841.
The conversation is about using distilled water as a solvent for topical finasteride to reduce systemic absorption. The user is considering avoiding ethanol and propylene glycol to achieve this.
CB 03 01 (Breezula) was tried for hair loss but showed no significant improvement, with issues in dissolving and application. Finasteride and dutasteride remain the most effective treatments, while minoxidil is also used; CB's effectiveness is questioned, and topical alternatives like bicalutamide are considered.
CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.
The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.
Bicalutamide is discussed as a treatment for hair loss, particularly in females, with some users cautioning against its use due to potential side effects. The conversation also mentions using finasteride and other anti-androgens, with some users recommending more traditional treatments like dutasteride.
Winlevi is being considered for hair loss by someone who wants to avoid systemic hormonal changes. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.
A 21-year-old male experienced side effects from topical finasteride and is seeking alternative treatments to maintain hair until Breezula is available. He is considering using minoxidil, Nizoral, micro-needling, and vitamin D supplementation, and may try CB or RU58841 if necessary.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
The conversation discusses whether to wait for Breezula while using topical minoxidil to avoid side effects from finasteride. It mentions Breezula's potential release in a year and its cost and long-term use considerations.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
Winlevi (clascoterone), a DHT blocker, is being considered for hair loss treatment, though it's primarily an acne medication. Users discuss its potential effectiveness and note it may only work for a short time.
Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.
Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.
CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.
A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.
The user diagnosed with DUPA tried treatments like dutasteride, finasteride, RU58841, and minoxidil without success and is considering a hair system. They hope for a future cure, possibly with PP405, and others suggest options like scalp biopsy and SMP.
The user is experiencing severe hair loss despite using treatments like DUT, oral minoxidil, ketoconazole, RU58841, and vitamins. They plan to buzz their hair due to the ongoing hair fall and its impact on their mental health and self-esteem.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.
The user's decision to shave their head rather than continue using drugs like finasteride and minoxidil to try and stop hair loss, as well as other suggestions such as scalp micropigmentation.
PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.
A user has been losing hair for two and a half years after a tropical trip and illness. A dermatologist prescribed betamethasone valerate 0.1% lotion, but the user is unsure if it's safe or effective for general hair loss.
A 23-year-old man with hair loss, despite using dutasteride, oral minoxidil, and RU58841, is considering bicalutamide for regrowth but is concerned about feminization. Alternatives like topical estrogen, JXL069, and spironolactone are discussed, with suggestions to explore thyroid levels and other potential underlying conditions.